Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Mereo BioPharma Group plcNASDAQ: MREO

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$8.75M, compared with -$11.2M a year earlier. Trailing-twelve-month operating income was -$37.66M.

Context

  • Operating income amounted to 7651.4% of revenue in FY2025.
  • Operating income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 4 analysts of -$8.81M (+77.0%) for the fiscal year ending Dec 2026, a step up from the +19.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.75M-4.3% QoQ
Last fiscal yearDec 2025
-$38.26M+19.2% YoY
LTMMar 2026
-$37.66M+22.4% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.9%+87.9%+66.0 pp
1 year+19.2%+77.0%+57.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(38.26M) USD
Year-over-year change
+19.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +22.4% is the 2nd highest of 10, against a peer median of -39.8%.
  • Operating income amounts to 7531.1% of revenue for MREO, versus a peer median of 2127.7%.
MREO Competitors
Operating Income for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$28.38M USD+53.6%——
MREOMereo BioPharma Group plcLTM Mar 2026-$37.66M USD+22.4%—7531.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€46.45M EUR-39.8%—345.5%
CADLCandel Therapeutics, Inc.LTM Mar 2026-$56.42M USD-67.9%——
ACIUAC Immune S.A.LTM Mar 2026-CHF 64.75M CHF-25.3%—1749.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$66.85M USD-256.5%——
SLNSilence Therapeutics plcLTM Mar 2026-$86.59M USD——9396.6%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$97.79M USD+15.9%——
CAPRCapricor Therapeutics, Inc.LTM Mar 2026-$119.93M USD-109.4%——
IMMPImmutep LimitedFY2025-A$126.42M AUD-43.5%—2506.5%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026-$163.79M USD-1.9%——
Peer median (excluding MREO) —-39.8%—2127.7%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.